Research programme: membrane protein inhibitor/antibacterial combinations - Rempex PharmaceuticalsAlternative Names: MP-01,028
Latest Information Update: 16 Dec 2013
At a glance
- Originator Mpex Pharmaceuticals
- Developer The Medicines Company
- Mechanism of Action Cell wall inhibitors; Membrane protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Gram-negative infections